Skip to main content

29-04-2020 | Type 2 diabetes | Podcast | Article

Is oral semaglutide a game changer or nice-to-have for type 2 diabetes?


With oral semaglutide now available in the USA and Europe, what part is it likely to play in the treatment of people with type 2 diabetes in primary care?

Neil Skolnik, Professor of Family and Community Medicine at Sidney Kimmel Medical College in Philadelphia, Pennysylvania, USA, gives his view and outlines key considerations for the use of this new medication as part of a shared decision-making process with people who have type 2 diabetes.

Listen below or subscribe to this podcast on:

Apple Podcasts | Spotify | Google PodcastsStitcher | TuneIn

About the expert

Neil Skolnik

Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students in the family medicine residency program at Abington Jefferson Health in Abington, Pennsylvania. Disclosures

Full biography


Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »